Clinical trials and clinical practice - bridging the gaps in type 2 diabetes - An evidence-based approach to risk factor modification in type 2 diabetes

被引：4
|
作者：
Greenfield, JR
Chisholm, DJ
机构：
[1] St Vincents Hosp, Dept Endocrinol, Sydney, NSW, Australia
[2] Garvan Inst Med Res, Sydney, NSW, Australia
[3] Univ New S Wales, Sydney, NSW, Australia
来源：
AUSTRALIAN AND NEW ZEALAND JOURNAL OF MEDICINE | 2000年 / 30卷 / 04期
关键词：
D O I：
10.1111/j.1445-5994.2000.tb02056.x
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
[No abstract available]
引用
收藏
页码：483 / 491
页数：9
相关论文
共 50 条
  • [41] The impact of genetic studies of type 2 diabetes on clinical practice
    Steven C. Elbein
    [J]. Current Diabetes Reports, 2003, 3 (2) : 93 - 94
  • [42] Sitagliptin Versus Ipragliflozin for Type 2 Diabetes in Clinical Practice
    Matsuba, Ikuro
    Iemitsu, Kotaro
    Kawata, Takehiro
    Iizuka, Takashi
    Takihata, Masahiro
    Takai, Masahiko
    Nakajima, Shigeru
    Minami, Nobuaki
    Umezawa, Shinichi
    Kanamori, Akira
    Takeda, Hiroshi
    Ito, Shogo
    Kikuchi, Taisuke
    Amcmiya, Hikaru
    Kaneshiro, Mizuki
    Mokubo, Atsuko
    Takuma, Tetsuro
    Machimura, Hideo
    Tanaka, Keiji
    Asakura, Taro
    Kubota, Akira
    Aoyagi, Sachio
    Hoshino, Kazuhiko
    Ishikawa, Masashi
    Obana, Mitsuo
    Sasai, Nobuo
    Kaneshige, Hideaki
    Miyakawa, Masaaki
    Tanaka, Yasushi
    Terauchi, Yasuo
    [J]. JOURNAL OF ENDOCRINOLOGY AND METABOLISM, 2019, 9 (05) : 151 - 158
  • [43] New practice in semaglutide on type-2 diabetes and obesity: clinical evidence and expectation
    Yalin Liu
    Xianghang Luo
    [J]. Frontiers of Medicine, 2022, 16 : 17 - 24
  • [44] New practice in semaglutide on type-2 diabetes and obesity:clinical evidence and expectation
    Yalin Liu
    Xianghang Luo
    [J]. Frontiers of Medicine, 2022, 16 (01) - 24
  • [45] New practice in semaglutide on type-2 diabetes and obesity: clinical evidence and expectation
    Liu, Yalin
    Luo, Xianghang
    [J]. FRONTIERS OF MEDICINE, 2022, 16 (01) : 17 - 24
  • [46] Multifactorial risk factor control in clinical practice and risk of cardiovascular disease in type 2 diabetes: report from the Swedish national diabetes register
    Eeg-Olofsson, K.
    Gudbjornsdottir, S.
    Eliasson, B.
    Zethelius, B.
    Svensson, A. -M.
    Cederholm, J.
    [J]. DIABETOLOGIA, 2014, 57 : S493 - S493
  • [47] A European Evidence-Based Guideline for the Prevention of Type 2 Diabetes
    Paulweber, B.
    Valensi, P.
    Lindstrom, J.
    Lalic, N. M.
    Greaves, C. J.
    McKee, M.
    Kissimova-Skarbek, K.
    Liatis, S.
    Cosson, E.
    Szendroedi, J.
    Sheppard, K. E.
    Charlesworth, K.
    Felton, A. -M.
    Hall, M.
    Rissanen, A.
    Tuomilehto, J.
    Schwarz, P. E.
    Roden, M.
    [J]. HORMONE AND METABOLIC RESEARCH, 2010, 42 : S3 - S36
  • [48] Should the algorithm for the treatment of type 2 diabetes be evidence-based?
    Guillausseau, P-J
    [J]. DIABETOLOGIA, 2010, 53 (09) : 2076 - 2077
  • [49] Evidence-based treatment of hypertension in patients with type 2 diabetes
    De Vriese, A
    [J]. ACTA CLINICA BELGICA, 2001, 56 (02) : 96 - 102
  • [50] Should the algorithm for the treatment of type 2 diabetes be evidence-based?
    P.-J. Guillausseau
    [J]. Diabetologia, 2010, 53 : 2076 - 2077
12345